404 related articles for article (PubMed ID: 25804827)
1. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
Glavey SV; Ghobrial IM
Expert Rev Hematol; 2015 Jun; 8(3):273-5. PubMed ID: 25804827
[TBL] [Abstract][Full Text] [Related]
2. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.
Terpos E;
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):321-334. PubMed ID: 29576386
[TBL] [Abstract][Full Text] [Related]
3. 57th American Society of Hematology Annual Meeting.
Smith LL
Lancet Oncol; 2016 Feb; 17(2):142. PubMed ID: 26687594
[No Abstract] [Full Text] [Related]
4. Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.
Saburi M; Ogata M; Soga Y; Kondo Y; Kurimoto R; Itani K; Kohno K; Uchida H; Nakayama T
J Clin Exp Hematop; 2020; 60(1):17-20. PubMed ID: 32224561
[No Abstract] [Full Text] [Related]
5. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
6. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016.
Terpos E;
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):329-339. PubMed ID: 28462890
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
8. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
Terpos E; Ntanasis-Stathopoulos I;
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371
[TBL] [Abstract][Full Text] [Related]
9. Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
Raje N; Faiman B; Harvey RD; Kurtin SE; Lonial S; Kumar SK; Cohen AD; Conde MA; Giralt SA; Recine MS; Tombler ER; Stadtmauer E; Jagannath S; Anderson KC;
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):356-69. PubMed ID: 25066040
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
11. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Holstein SA; Al-Kadhimi Z; Costa LJ; Hahn T; Hari P; Hillengass J; Jacob A; Munshi NC; Oliva S; Pasquini MC; Shi Q; Stadtmauer EA; Waldvogel SL; McCarthy PL
Biol Blood Marrow Transplant; 2020 Jan; 26(1):e7-e15. PubMed ID: 31526843
[TBL] [Abstract][Full Text] [Related]
12. 49th Annual Meeting of the American Society of Hematology, Atlanta, GA; December 8-11, 2007.
Clin Lymphoma Myeloma; 2008 Apr; 8(2):77-86. PubMed ID: 18564453
[No Abstract] [Full Text] [Related]
13. Geriatric Hematology Research presented at the 2018 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology Perspective Paper.
Loh KP; Christofyllakis K; Huang LW; Mims A
J Geriatr Oncol; 2019 Mar; 10(2):186-191. PubMed ID: 30661875
[No Abstract] [Full Text] [Related]
14. American Society of Clinical Oncology 41st annual meeting.
Dillman RO
Expert Opin Biol Ther; 2005 Aug; 5(8):1117-27. PubMed ID: 16050788
[TBL] [Abstract][Full Text] [Related]
15. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
Holstein SA; Avet-Loiseau H; Hahn T; Ho CM; Lohr JG; Munshi NC; Paiva B; Pasquini MC; Tario JD; Usmani SZ; Wallace PK; Weisel K; McCarthy PL
Biol Blood Marrow Transplant; 2018 Apr; 24(4):641-648. PubMed ID: 29242112
[TBL] [Abstract][Full Text] [Related]
16. The effect of novel therapies in high-molecular-risk multiple myeloma.
Lancman G; Tremblay D; Barley K; Barlogie B; Cho HJ; Jagannath S; Madduri D; Moshier E; Parekh S; Chari A
Clin Adv Hematol Oncol; 2017 Nov; 15(11):870-879. PubMed ID: 29200420
[TBL] [Abstract][Full Text] [Related]
17. The pharmacologic management of multiple myeloma in older adults.
Dempsey JL; Johns A; Rosko AE; Lazarus HM
Expert Opin Pharmacother; 2019 May; 20(7):887-902. PubMed ID: 30785310
[TBL] [Abstract][Full Text] [Related]
18. Meeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
Merz M; Hillengass J; Goldschmidt H
J Cancer Res Clin Oncol; 2016 Jan; 142(1):247-51. PubMed ID: 26068597
[TBL] [Abstract][Full Text] [Related]
19. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy in multiple myeloma.
Mihelic R; Kaufman JL; Lonial S
Leukemia; 2007 Jun; 21(6):1150-7. PubMed ID: 17344913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
